Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960085 | 0.84 | ALDH1A1 (0.57) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL7488352 | 0.82 | ALDH1A1 (0.54) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL25210162 | 0.78 | L3MBTL1 (0.57) | ALDH1A1KMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL3927688 | 0.77 | KMT2A (0.58) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL11147008 | 0.77 | CNR1 (0.60) | ALDH1A1KMT2AOPRM1OPRD1KDM4E | |
| SCHEMBL13977996 | 0.76 | ALDH1A1 (0.54) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL11148885 | 0.76 | KMT2A (0.56) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL9192054 | 0.76 | KMT2A (0.46) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL2088176 | 0.75 | KMT2A (0.56) | ALDH1A1KMT2AOPRM1OPRD1KDM4E | |
| SCHEMBL16000808 | 0.74 | KMT2A (0.54) | ALDH1A1KMT2AOPRM1OPRD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090186876-A1 | Pyridine Analogues II | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| EP-2041111-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008002247-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20070244088-A1 | New Pyridine Analogues II | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | ALDH1A1 1820/4885KMT2A 4642/4885OPRM1 1022/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | ALDH1A1 1638/4885KMT2A 4406/4885OPRM1 1459/4885 |
| US-20070244088-A1 | New Pyridine Analogues II | P2RY12, P2RY1, P2RY11 | ALDH1A1 2018/4885KMT2A 4222/4885OPRM1 1424/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | ALDH1A1 1274/4885KMT2A 3584/4885OPRM1 1835/4885 |
| US-20090186876-A1 | Pyridine Analogues II | P2RY12, P2RY11, P2RY6 | ALDH1A1 1602/4885KMT2A 4221/4885OPRM1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.